Roles of naofen, a novel WD-repeat-2 protein, in the CCl4-treated livers--a possible relationship to cell proliferation.
Naofen (GenBank accession no. EF613262), a newly found intracellular protein in the WD-repeat-2 protein family, has been cloned as an anti-verotoxin II antibody immunoreactive substance, and the nucleotide- and amino acid-sequences have been clarified. The present study was undertaken to evaluate the roles of naofen especially in carbon tetrachloride (CCl4-induced cirrhosis model of rats, also in partial hepatectomy. Naofen mRNA expressions were observed from the early phases of cirrhosis development and during regenerative phases after partial hepatectomy, more remarkable in the former. Naofen immunoreactive fragments located in the vascular endothelial cells and peri-vascular spaces in normal livers especially in Glisson's areas, being strongly stained in the connective tissues 8 weeks after starting CCl4-injections, besides in the cytoplasm of hepatocytes in pseudo-lobules. In contrast, partial hepatectomy caused a small increase of naofen expressions in the whole hepatocytes, and significantly in the endothelial cells of portal veins and hepatic arterioles. Furthermore, in parallel to the degree of naofen mRNA and protein expressions, the rates of double-nuclei cells to total hepatocytes in the Glisson's areas increased in both cirrhosis and partial hepatectomy, suggesting a relationship between naofen expression and mitosis. In in-vitro studies with cell lines, vascular endothelial growth factor, a cell proliferation stimulant, increased the naofen mRNA expressions in HepG(2) cell lines, whereas paclitaxel, a cytotoxic anti-cancer drug, diminished them in NRK52E, both concentration-dependently. These results indicated that naofen immunoreactive fragments play an important role in the cell proliferation, relevant for analyzing the regenerative phases during cirrhosis developments and after partial hepatectomy.
An
Jun
J
Department of Pharmacology, Aichi Medical University School of Medicine, Nagakute, Aichi pref., 480-1195, Japan.
Tsunekawa
Koji
K
Feng
Guo Gang
GG
Li
Chang
C
Huang
Lei
L
Ito
Yoshitake
Y
Sugiyama
Satoru
S
Kurokawa
Tsuyoshi
T
Koide
Tatsuro
T
Nonami
Toshiaki
T
Ishikawa
Naohisa
N
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D002252:Carbon Tetrachloride Poisoning / Q000473:pathology*; D002452:Cell Count; D002460:Cell Line; D049109:Cell Proliferation; D002478:Cells, Cultured; D006498:Hepatectomy; D022781:Hepatocytes / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D007700:Kinetics; D008099:Liver / Q000378:metabolism; D008106:Liver Cirrhosis, Experimental / Q000139:chemically induced / Q000473:pathology*; D008297:Male; D008938:Mitosis / Q000502:physiology; D017239:Paclitaxel / Q000494:pharmacology; D011506:Proteins / Q000235:genetics / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D020133:Reverse Transcriptase Polymerase Chain Reaction; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis
D000972:Antineoplastic Agents, Phytogenic; D011506:Proteins; D042461:Vascular Endothelial Growth Factor A; C582790:WDR35 protein, rat; D017239:Paclitaxel